Mainz Biomed BV
NASDAQ:MYNZ

Watchlist Manager
Mainz Biomed BV Logo
Mainz Biomed BV
NASDAQ:MYNZ
Watchlist
Price: 1.03 USD -1.9% Market Closed
Market Cap: 5.6m USD

Net Margin
Mainz Biomed BV

-2 874.8%
Current
-2 672%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 874.8%
=
Net Income
-19m
/
Revenue
659.9k

Net Margin Across Competitors

No Stocks Found

Mainz Biomed BV
Glance View

Market Cap
5.6m USD
Industry
Biotechnology

Mainz Biomed BV operates as a biotechnology company. The company is headquartered in Mainz, Hessen. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

MYNZ Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 874.8%
=
Net Income
-19m
/
Revenue
659.9k
What is the Net Margin of Mainz Biomed BV?

Based on Mainz Biomed BV's most recent financial statements, the company has Net Margin of -2 874.8%.

Back to Top